Sublingual Immunotherapy in Allergic Rhinitis: Efficacy, Safety, Adherence and Guidelines

Overview

Journal Clin Exp Otorhinolaryngol

Date 2014 Dec 2

PMID 25436040

Citations 7

Authors

Omar Ali Aboshady

Karim Mohamed Elghanam

Affiliations

Soon will be listed here.

Abstract

Allergic rhinitis (AR) is a globally increasing health problem affecting the quality of life. Specific immunotherapy is an available causal treatment changing the basic allergic mechanisms of the disease. Over one hundred years, subcutaneous immunotherapy (SCIT) was developed and proved its efficacy but many adverse effects were recorded including anaphylaxis. In 1986, sublingual immunotherapy (SLIT) was introduced as an alternative solution to solve this problem. Our study aims to discuss SLIT from the points of efficacy, safety, adherence and guidelines developed. A literature search was conducted in Medline/PubMed and the Cochrane Library in January 2013 using the keywords "allergic rhinitis, sublingual immunotherapy, efficacy, safety, compliance, adherence, guidelines." All types of publications were included. We augmented our study by searching the reference lists of identified reviews. SLIT has been established in many guidelines as an evidence-based effective treatment in AR with safer profile than SCIT. The meta-analyses confirmed its efficacy and showed a significant reduction in both symptoms and medication scores. The most common recorded adverse effects were minor local effects in the mouth, gastrointestinal reactions with few cases of anaphylaxis and no fatality. Adherence is more favorable for SLIT mainly because it is safe, noninvasive and easily taken at home. We support the call to conduct large multi-centric studies to gain more statistical power and overcome the problem of heterogeneity observed in the meta-analyses.

Citing Articles

Management of Allergic Rhinitis in the United Arab Emirates: Expert Consensus Recommendations on Allergen Immunotherapy.

Zaitoun F, Al Hameli H, Karam M, Gutta R, Wustenberg E, Arora T Cureus. 2024; 16(7):e65260.

PMID: 39184659 PMC: 11342581. DOI: 10.7759/cureus.65260.

Executive Summary of Clinical Practice Guideline on Immunotherapy for Inhalant Allergy.

Gurgel R, Baroody F, Damask C, Mims J, Ishman S, Baker D Otolaryngol Head Neck Surg. 2024; 170(3):635-667.

PMID: 38408153 PMC: 11748194. DOI: 10.1002/ohn.650.

Clinical Practice Guideline: Immunotherapy for Inhalant Allergy.

Gurgel R, Baroody F, Damask C, Mims J, Ishman S, Baker Jr D Otolaryngol Head Neck Surg. 2024; 170 Suppl 1:S1-S42.

PMID: 38408152 PMC: 11788925. DOI: 10.1002/ohn.648.

Malaysian Society of Allergy and Immunology Consensus Statement on Sublingual Immunotherapy in Allergic Rhinitis.

Abdullah B, Pawankar R, Abdul Latiff A, Woo K, Wustenberg E, Khalid M J Clin Med. 2023; 12(3).

PMID: 36769797 PMC: 9918058. DOI: 10.3390/jcm12031151.

Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis.

Cheng L, Chen J, Fu Q, He S, Li H, Liu Z Allergy Asthma Immunol Res. 2018; 10(4):300-353.

PMID: 29949830 PMC: 6021586. DOI: 10.4168/aair.2018.10.4.300.

References

Bahceciler N, Galip N, Cobanoglu N . Multiallergen-specific immunotherapy in polysensitized patients: where are we?. Immunotherapy. 2013; 5(2):183-90. DOI: 10.2217/imt.12.161. View

Dunsky E, Goldstein M, Dvorin D, Belecanech G . Anaphylaxis to sublingual immunotherapy. Allergy. 2006; 61(10):1235. DOI: 10.1111/j.1398-9995.2006.01137.x. View

Kawauchi H, Goda K, Tongu M, Yamada T, Aoi N, Morikura I . Short review on sublingual immunotherapy for patients with allergic rhinitis: from bench to bedside. Adv Otorhinolaryngol. 2011; 72:103-6. DOI: 10.1159/000324631. View

Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G . Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006; 97(2):141-8. DOI: 10.1016/S1081-1206(10)60004-X. View

Canonica G, Bousquet J, Casale T, Lockey R, Baena-Cagnani C, Pawankar R . Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2010; 64 Suppl 91:1-59. DOI: 10.1111/j.1398-9995.2009.02309.x. View

Scadding G, Brostoff J . Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy. 1986; 16(5):483-91. DOI: 10.1111/j.1365-2222.1986.tb01983.x. View

Incorvaia C, Mauro M, Ridolo E, Puccinelli P, Liuzzo M, Scurati S . Patient's compliance with allergen immunotherapy. Patient Prefer Adherence. 2009; 2:247-51. PMC: 2770419. DOI: 10.2147/ppa.s3806. View

Rhodes B . Patient dropouts before completion of optimal dose, multiple allergen immunotherapy. Ann Allergy Asthma Immunol. 1999; 82(3):281-6. DOI: 10.1016/S1081-1206(10)62609-9. View

Schunemann H, Jaeschke R, Cook D, Bria W, El-Solh A, Ernst A . An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med. 2006; 174(5):605-14. DOI: 10.1164/rccm.200602-197ST. View

10.

Noon L . Prophylactic inoculation against hay fever. Int Arch Allergy Appl Immunol. 1953; 4(4):285-8. DOI: 10.1159/000228032. View

11.

Zuberbier T, Bachert C, Bousquet P, Passalacqua G, Canonica G, Merk H . GA² LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010; 65(12):1525-30. DOI: 10.1111/j.1398-9995.2010.02474.x. View

12.

Olaguibel J, Alvarez Puebla M . Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol. 2005; 15(1):9-16. View

13.

Calderon M, Casale T, Togias A, Bousquet J, Durham S, Demoly P . Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol. 2010; 127(1):30-8. DOI: 10.1016/j.jaci.2010.08.024. View

14.

Fiocchi A, Pajno G, La Grutta S, Pezzuto F, Incorvaia C, Sensi L . Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol. 2005; 95(3):254-8. DOI: 10.1016/S1081-1206(10)61222-7. View

15.

Brozek J, Bousquet J, Baena-Cagnani C, Bonini S, Canonica G, Casale T . Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126(3):466-76. DOI: 10.1016/j.jaci.2010.06.047. View

16.

Marogna M, Spadolini I, Massolo A, Canonica G, Passalacqua G . Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010; 126(5):969-75. DOI: 10.1016/j.jaci.2010.08.030. View

17.

Di Rienzo V, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica W . Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy. 2005; 35(5):560-4. DOI: 10.1111/j.1365-2222.2005.02219.x. View

18.

Passalacqua G . Specific immunotherapy: beyond the clinical scores. Ann Allergy Asthma Immunol. 2011; 107(5):401-6. DOI: 10.1016/j.anai.2011.04.017. View

19.

Passalacqua G, Musarra A, Pecora S, Amoroso S, Antonicelli L, Cadario G . Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year). J Allergy Clin Immunol. 2006; 117(4):946-8. DOI: 10.1016/j.jaci.2005.12.1312. View

20.

Eifan A, Keles S, Bahceciler N, Barlan I . Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy. 2007; 62(5):567-8. DOI: 10.1111/j.1398-9995.2006.01301.x. View